Chronic overconsumption of sugar and fat elevates plasma levels of insulin and free fatty acids, a process referred to as glucolipotoxicity. This phenomenon may lead to heart failure. This issue explores in depth the relationship between glucolipotoxicity and heart failure.
Pulmonary hypertension (PH) is increased pressure in the pulmonary arteries, which carry blood from the heart to the lungs to pick up oxygen. The changes resulting from PH make it difficult for the heart to push blood through the pulmonary arteries, causing the heart to become weak and possibly to develop failure. Understanding the causes and treatment of PH can help heart failure specialists prevent heart failure due to PH.
This issue of Heart Failure Clinics covers stress (takotsubo) cardiomyopathy. Expert authors review the most current information available about imaging modalities, clinical profile, natural history, management, and different types of stress cardiomyopathy. Keep up-to-the-minute with the latest developments in diagnosing and managing this condition.
This issue of Heart Failure Clinics is about acute decompensated heart failure. Expert authors review the most current information available about comorbidities, management, drug therapy, and strategies to prevent a post-discharge adverse event. Keep up-to-the-minute with the latest developments in this life-threatening disorder.
Chronic overconsumption of sugar and fat elevates plasma levels of insulin and free fatty acids, a process referred to as glucolipotoxicity. This phenomenon may lead to heart failure. This issue explores in depth the relationship between glucolipotoxicity and heart failure.
In the joint American College of Cardiology /American Heart Association classification system, Stage B heart failure refers to patients with structural heart disease but no symptoms of heart failure. Preventing progression of heart failure in Stage B patients is a central concern to heart failure specialists, so two issues have been devoted to this topic. Part I focuses on an understanding of structural heart disease and the factors that cause progression from risk of heart failure to development of structural changes.
Emergency physicians are usually the first to care for patients with emergency cardiac conditions. They must initiate therapy in a timely manner and must plan care in conjunction with cardiologists, who continue the patient's care. This issue has both emergency physicians and cardiologists as authors, reflecting the fact that both care for patients with cardiac emergencies. Physicians in both disciplines should benefit from the articles in this issue, resulting in better patient care.
In the joint American College of Cardiology /American Heart Association classification system, Stage B heart failure refers to patients with structural heart disease but no symptoms of heart failure. Preventing progression of heart failure in Stage B patients is a central concern to heart failure specialists, so two issues have been devoted to this topic. Part II focuses on screening to identify patients with Stage B HF and monitoring and therapeutic approaches to patients with a diagnosis of Stage B HF.
This issue of Heart Failure Clinics, guest edited by Geu-Ru Hong, will cover key topics in Heart Failure with Preserved Ejection Fraction. This issue is one of four selected each year by our series consulting editor, Dr. Eduardo Bossone. Topics discussed in this issue will include: Current Trends and Outcomes of Heart Failure with Preserved Ejection Fraction, Pathogenesis and Phenotypes of Heart Failure with Preserved Ejection Fraction, Hypertension and Heart Failure with Preserved Ejection Fraction, Obesity in Heart Failure with Preserved Ejection Fraction, Noninvasive Hemodynamic Evaluation at rest in Heart Failure with Preserved Ejection Fraction, Clinical Phenogroups in Heart?Failure With Preserved Ejection Fraction and response to therapy, among others.
Up-to-date, authoritative and comprehensive, Heart Failure, 4th Edition, provides the clinically relevant information you need to effectively manage and treat patients with this complex cardiovascular problem. This fully revised companion to Braunwald's Heart Disease helps you make the most of new drug therapies such as angiotensin receptor neprilysin inhibitors (ARNIs), recently improved implantable devices, and innovative patient management strategies. Led by internationally recognized heart failure experts Dr. G. Michael Felker and Dr. Douglas Mann, this outstanding reference gives health care providers the knowledge to improve clinical outcomes in heart failure patients. - Focuses on a clinical approach to treating heart failure, resulting from a broad variety of cardiovascular problems. - Covers the most recent guidelines and protocols, including significant new updates to ACC, AHA, and HFSA guidelines. - Covers key topics such as biomarkers and precision medicine in heart failure and new data on angiotensin receptor neprilysin inhibitors (ARNIs). - Contains four new chapters: Natriuretic Peptides in Heart Failure; Amyloidosis as a Cause of Heart Failure; HIV and Heart Failure; and Neuromodulation in Heart Failure. - Covers the pathophysiological basis for the development and progression of heart failure. - Serves as a definitive resource to prepare for the ABIM's Heart Failure board exam. - 2016 British Medical Association Award: First Prize, Cardiology (3rd Edition).